#ATNM hashtag - Bluesky

Investors in Actinium Pharmaceuticals Can Discuss Rights Before May 2025 Deadline Actinium Pharmaceuticals investors have until May 27, 2025, to contact Levi & Korsinsky regarding their rights and a class action lawsuit for alleged securities fraud.

10 months ago

Investors in Actinium Pharmaceuticals Can Discuss Rights Before May 2025 Deadline #United_States #New_York #Levi_&_Korsinsky #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Pomerantz Law Firm Alerts Investors of Class Action Against Actinium Pharmaceuticals: Key Details and Next Steps Pomerantz Law Firm has filed a class action lawsuit against Actinium Pharmaceuticals, urging investors with losses to take timely action. Important deadlines and details inside.

10 months ago

Pomerantz Law Firm Alerts Investors of Class Action Against Actinium Pharmaceuticals: Key Details and Next Steps #United_States #New_York #Pomerantz_Law_Firm #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Actinium Pharmaceuticals Faces Securities Law Suit: Shareholder Rights Noticed Actinium Pharmaceuticals, Inc. has been sued for alleged securities law violations, and investors should contact The Gross Law Firm before May 27, 2025, to discuss their rights.

10 months ago

Actinium Pharmaceuticals Faces Securities Law Suit: Shareholder Rights Noticed #United_States #New_York #Securities_Law #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Investors Take Action Against Actinium Pharmaceuticals for Misleading Statements A class action has been filed against Actinium Pharmaceuticals, Inc. to recover losses incurred by shareholders. Investors are encouraged to participate.

10 months ago

Investors Take Action Against Actinium Pharmaceuticals for Misleading Statements #USA #New_York #Class_Action #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center Actinium Pharmaceuticals (NYSE: ATNM) has enrolled its first patient in a groundbreaking trial of Iomab-ACT, a targeted radiotherapy conditioning agent, with commercial CAR-T therapy at the University of Texas Southwestern Medical Center. Initial clinical data is expected in H2 2025. The trial aims to replace traditional chemotherapy conditioning agents with Iomab-ACT to reduce serious CAR-T related toxicities. The technology targets CD45, a cell surface marker on immune cells, and has shown promising results in previous trials with zero cases of ICANS and minimal CRS. This development could significantly impact the CAR-T therapy market, which generated $4 billion in sales in 2024 and is projected to reach $12 billion by 2030. The addressable market includes approximately 150,000 patients annually across approved CAR-T therapy indications.

10 months ago

#ATNM Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

www.stocktitan.net/news/ATNM/actinium-annou...

0 0 0 0

Investors Alert: Actinium Pharmaceuticals Faces Class Action Lawsuit for Securities Fraud Allegations Actinium Pharmaceuticals, Inc. is currently facing a class action lawsuit regarding securities law violations, affecting investors. Act quickly to learn more.

10 months ago

Investors Alert: Actinium Pharmaceuticals Faces Class Action Lawsuit for Securities Fraud Allegations #United_States #New_York #securities_lawsuit #Actinium #ATNM

0 0 0 0

Actinium Pharmaceuticals Faces Class Action Lawsuit: Investors Urged to Act Swiftly Levi & Korsinsky LLP has alerted investors about a class action lawsuit against Actinium Pharmaceuticals. Affected shareholders should act by May 27, 2025.

11 months ago

Actinium Pharmaceuticals Faces Class Action Lawsuit: Investors Urged to Act Swiftly #USA #New_York #Levi_&_Korsinsky #Actinium #ATNM

0 0 0 0

Levi & Korsinsky Initiates Class Action Against Actinium Pharmaceuticals for Investor Recovery Levi & Korsinsky has filed a class action lawsuit against Actinium Pharmaceuticals for alleged securities fraud, impacting investors. Get details on the case.

11 months ago

Levi & Korsinsky Initiates Class Action Against Actinium Pharmaceuticals for Investor Recovery #United_States #New_York #Class_Action #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Legal Action Announced Against Actinium Pharmaceuticals for Potential Securities Fraud Investors in Actinium Pharmaceuticals are alerted to a class action lawsuit regarding alleged securities fraud with impending deadlines for participation.

11 months ago

Legal Action Announced Against Actinium Pharmaceuticals for Potential Securities Fraud #USA #New_York #Pomerantz_LLP #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Investors Urged to Join Class Action Against Actinium Pharmaceuticals Before May 2025 Deadline Shareholders of Actinium Pharmaceuticals, Inc. are invited to join a class action lawsuit regarding misleading statements about the FDA approval of a key treatment. The deadline is May 27, 2025.

11 months ago

Investors Urged to Join Class Action Against Actinium Pharmaceuticals Before May 2025 Deadline #United_States #New_York #Gross_Law_Firm #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Levi & Korsinsky Alerts Actinium Pharmaceuticals Investors on Class Action Deadline Levi & Korsinsky warns Actinium Pharmaceuticals investors about the upcoming lead plaintiff deadline for a class action lawsuit. Act quickly and join the case by May 27, 2025.

11 months ago

Levi & Korsinsky Alerts Actinium Pharmaceuticals Investors on Class Action Deadline #United_States #New_York #Levi_Korsinsky #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Key Deadline Approaches for Actinium Pharmaceuticals Shareholders as Legal Team Mobilizes The Gross Law Firm highlights an important lead plaintiff deadline of May 27, 2025, for shareholders of Actinium Pharmaceuticals, Inc., involved in a class action lawsuit.

11 months ago

Key Deadline Approaches for Actinium Pharmaceuticals Shareholders as Legal Team Mobilizes #United_States #New_York #Gross_Law_Firm #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Pomerantz Law Firm Issues Urgent Class Action Alert for Actinium Pharmaceuticals Investors The Pomerantz Law Firm alerts investors of a class action lawsuit against Actinium Pharmaceuticals, claiming securities fraud. Key deadlines are approaching.

11 months ago

Pomerantz Law Firm Issues Urgent Class Action Alert for Actinium Pharmaceuticals Investors #USA #New_York #Pomerantz_LLP #Actinium #ATNM

0 0 0 0

Actinium Pharmaceuticals Investors Alerted to Class Action Lawsuit by Gross Law Firm with Important Dates The Gross Law Firm informs investors of Actinium Pharmaceuticals about a class action lawsuit. Key deadlines and necessary actions are detailed.

11 months ago

Actinium Pharmaceuticals Investors Alerted to Class Action Lawsuit by Gross Law Firm with Important Dates #USA #New_York #Gross_Law_Firm #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Actinium Pharmaceuticals Faces Class Action Lawsuit Over Investor Claims of Deception Investors in Actinium Pharmaceuticals have the chance to join a class action lawsuit led by Bronstein, Gewirtz & Grossman LLC after significant losses.

11 months ago

Actinium Pharmaceuticals Faces Class Action Lawsuit Over Investor Claims of Deception #USA #New_York #Bronstein_Gewirtz #Actinium_Pharmaceuticals #ATNM

0 0 0 0

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 Actinium Pharmaceuticals (NYSE: ATNM) has unveiled ATNM-400, a groundbreaking non-PSMA targeting radiotherapy for prostate cancer using Actinium-225. Initial preclinical data showed remarkable results with 99.8% tumor growth inhibition at 40 µCi/kg and 68.5% at 20 µCi/kg from a single dose.The therapy demonstrated selective tumor accumulation for up to 144 hours with minimal uptake in healthy tissues. ATNM-400 differentiates itself from Novartis's Pluvicto by targeting a different marker than PSMA and utilizing the more potent alpha-particle emitter Ac-225, potentially resulting in fewer off-target effects.The company will present initial data at the AACR Annual Meeting (April 25-30, 2025), including results from Pluvicto-resistant prostate cancer models. The presentation will showcase findings from in vitro and in vivo studies, biodistribution imaging, and efficacy analyses at various dose levels.

1 year ago

#ATNM Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

www.stocktitan.net/news/ATNM/actinium-pharm...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NYSE: #ATNM ) Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today

0 0 0 0

Major Breakthrough: Actinium Locks Critical Supply Deal for Revolutionary Cancer Treatment Development Strategic partnership ensures Ac-225 supply for advanced AML therapy and expanded solid tumor trials. Key milestone enables pivotal Phase 2/3 studies. Full analysis inside.

1 year ago

#ATNM Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

www.stocktitan.net/news/ATNM/actinium-pharm...

0 0 0 0

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy Actinium Pharmaceuticals (NYSE: ATNM) has announced a research collaboration with Memorial Sloan Kettering Cancer Center to expand Actimab-A's therapeutic applications. The partnership focuses on studying Actimab-A in combination with targeted therapies, particularly FLT3 and menin inhibitors, and assessing its activity in AML patient-derived samples.Actimab-A has shown positive clinical results in high-risk relapsed and refractory AML patients, including those with TP53 gene mutation, prior Venetoclax treatment, and bone marrow transplant. The therapy demonstrates synergy with various inhibitors targeting mutations present in significant portions of AML cases: NPM1 and KMT2A (30%), FLT3 (25-30%), and IDH1&2 (10-20%).The company is advancing Actimab-A into a pivotal Phase 2/3 trial in combination with CLAG-M chemotherapy for relapsed/refractory AML, and in newly diagnosed AML with Venetoclax and ASTX-727. Additionally, Actinium is developing Actimab-A for solid tumor indications, with planned trials combining it with KEYTRUDA® and OPDIVO® in HNSCC and NSCLC.

1 year ago

#ATNM Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

www.stocktitan.net/news/ATNM/actinium-pharm...

0 0 0 0

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® Actinium Pharmaceuticals (NYSE: ATNM) has announced a new clinical trial program combining Actimab-A with PD-1 checkpoint inhibitors KEYTRUDA® and OPDIVO® for solid tumors. The trials aim to improve patient outcomes by targeting Myeloid Derived Suppressor Cells (MDSCs) in the tumor microenvironment, which currently limit PD-1 inhibitors' effectiveness.The program includes controlled, head-to-head trials focusing on Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-Small Cell Lung Cancer (NSCLC). Initial proof of concept clinical data is expected in the second half of 2025. The company estimates a potential treatment population exceeding 500,000 patients.The trials will evaluate safety, tolerability, Overall Response Rate (ORR), Progression Free Survival (PFS), and Overall Survival (OS). Actimab-A, which has been studied in over 150 AML patients, delivers Actinium-225, targeting CD33-expressing MDSCs.

1 year ago

#ATNM Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

www.stocktitan.net/news/ATNM/actinium-pharm...

0 0 0 0